Northland Biotech Showcases Regenerative Medicine Innovation at the 90th China Pharmaceutical Trade Fair

May 07, 2025 07:31 CST Updated 07:31

Northland

Innovative Biopharmaceutical Manufacturer

"With the tide calm and the shores broad, the wind is fair for a single sail to hang." From May 21-23, 2025, the 90th China National Pharmaceutical Trade Fair will grandly open at the China Import and Export Fair Exhibition Hall in Guangzhou. Beijing Northland Biotechnology Co., Ltd. will make a stunning appearance with cutting-edge new technologies in regenerative medicine treatment, featuring its key project.-Cedomidine Injection, will beSevereNew Gene Therapy Offers Hope for Patients with Lower Limb Ischemic Diseases, Demonstrating China's Innovation in the Biopharmaceutical Field.

Since its establishment in 2004, Beijing Northland Biotechnology Co., Ltd. has consistently focused on the research and development of gene therapy drugs and recombinant protein drugs. With unwavering scientific determination, the company has continuously increased its R&D investment, establishing a comprehensive gene therapy drug R&D technology platform. After years of collaborative industry-university-research efforts, its core product, Cedominogene Injection, has been completed.Phase III clinical trials are expected to receive approval for market launch in 2025. This achievement is of great significance to China’s biopharmaceutical industry and also brings new hope to many patients suffering from severe lower limb ischemic diseases. According to authoritative data from the "China Cardiovascular Health and Disease Report 2022," the prevalence rate of lower limb ischemic diseases in the natural population aged ≥35 in China is 6.6%. Notably, among the vast patient population, the proportion of severe lower limb ischemic diseases is approximately...10%, which means that about 4.5 million patients in China are currently suffering from severe lower limb ischemic diseases.¹。

At this year's pharmaceutical trade fair, Northland has meticulously crafted Cedoming Injection.2.1H39 Exclusive Booth: A Comprehensive Presentation of the Drug Development Process, Mechanism of Action, and Clinical Advantages, Exploring Innovative Achievements with Visitors from All Directions. At the Concurrent First China Pharmaceutical Ecosystem Restructuring Forum, Northland will Deliver a Keynote Speech on "Gene Therapy Innovative Drugs: Commercial Expansion and Market Win-Win under Policy Benefits," Engaging in In-Depth Discussions with Agents and Industry Partners to Explore New Approaches for the Commercialization of Gene Therapy Drugs in China and Promote High-Quality Development of China’s Biopharmaceutical Industry.

"Long winds will break waves at the right time, and we'll set our cloud-like sails to cross the vast ocean." Amidst the flourishing development of the biopharmaceutical industry in China, let us look forward with great anticipation to Northland's brilliant debut at the 90th China National Pharmaceutical Trade Fair, and keep an eye on Cedominogene Injection for its contributions to the field of regenerative medicine treatment.LeadThe wave of innovation, looking forward to itsCritical Limb Ischemia in ChinaPatients bring moreNew Hope！

References:

1. National Center for Cardiovascular Diseases. Report on Cardiovascular Health and Diseases in China2022 [M]. Beijing: Peking Union Medical College Press, 2022.

END